Relugolix Patent Expiration
Relugolix is Used for the treatment of advanced prostate cancer in adult patients, specifically when the cancer is sex-hormone-dependent. It was first introduced by Sumitomo Pharma America Inc
Relugolix Patents
Given below is the list of patents protecting Relugolix, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Orgovyx | US10449191 | Treatment of prostate cancer | Sep 29, 2037 | Sumitomo Pharma Am |
| Orgovyx | US10786501 | Treatment of prostate cancer | Sep 29, 2037 | Sumitomo Pharma Am |
| Orgovyx | US11583526 | Treatment of prostate cancer | Sep 29, 2037 | Sumitomo Pharma Am |
| Orgovyx | US12097198 | Treatment of prostate cancer | Sep 29, 2037 | Sumitomo Pharma Am |
| Orgovyx | US12144809 | Treatment of prostate cancer | Sep 29, 2037 | Sumitomo Pharma Am |
| Orgovyx | US12336990 | Treatment of prostate cancer | Sep 29, 2037 | Sumitomo Pharma Am |
| Orgovyx | US12629370 | Treatment Of Prostate Cancer | Sep 29, 2037 | Sumitomo Pharma Am |
| Orgovyx | US10350170 | Solid preparation | Feb 25, 2036 | Sumitomo Pharma Am |
| Orgovyx | US11795178 | Compositions of thienopyrimidine derivatives | Sep 27, 2033 | Sumitomo Pharma Am |
| Orgovyx | US12325714 | Compositions of thienopyrimidine derivatives | Sep 27, 2033 | Sumitomo Pharma Am |
| Orgovyx | US7300935 | Thienopyrimidine compounds and use thereof | Jan 28, 2029 | Sumitomo Pharma Am |
| Orgovyx | US8058280 | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan 28, 2026
(Expired) | Sumitomo Pharma Am |
| Orgovyx | US8735401 | Thienopyrimidine compounds and use thereof |
Feb 04, 2024
(Expired) | Sumitomo Pharma Am |
Relugolix's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Relugolix:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| The SUGAR Study; SBRT and Relugolix) for Prostate Cancer | Yale University | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | NRG Oncology | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer | NYU Langone Health | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | Dana-Farber Cancer Institute | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients) | National Cancer Institute, Naples | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |